1. 945PA phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC). (23rd October 2018) Authors: O'Cearbhaill, R E; Wolfer, A; Disilvestro, P; O'Malley, D M; Sabbatini, P; Shohara, L; Schwarzenberger, P O; Ricciardi, T; Macri, M; Ryan, A; Venhaus, R R; Bryan, J K; Wong, P; Homicsko, K; Kandalaft, L; Rusakiewicz, S; Harari, A; Monk, B J; Coukos, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0059 The efficacy and safety of pegylated recombinant methionyl human soluble tumour necrosis factor receptor type i (peg stnf-ri; p55) in a randomised, placebo-controlled, clinical study of patients with rheumatoid arthritis (ra). (1st June 2001) Authors: Schiff, M; Furst, D; Fleischmann, R; Macri, M; Joh, T; Edwards, CK; Davis, MW Journal: Annals of the rheumatic diseases Issue: Volume 60(2001)Supplement 1 Page Start: A469 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Technical design report for the P̄ANDA Barrel DIRC detector *The use of registered names, trademarks, etc in this publication does not imply, even in the absence of specific statement, that such names are exempt from the relevant laws and regulations and therefore free for general use. (28th February 2019) Authors: Singh, B; Erni, W; Krusche, B; Steinacher, M; Walford, N; Liu, B; Liu, H; Liu, Z; Shen, X; Wang, C; Zhao, J; Albrecht, M; Erlen, T; Feldbauer, F; Fink, M; Fritsch, M; Haase, J; Heinsius, F H; Held, T; Holtmann, T Journal: Journal of physics Issue: Volume 46:Number 4(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗